Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
781-800 of 991 trials

Myelodysplastic Syndromes: Elritercept Treatment Study

We are testing elritercept to see if it can help reduce the need for blood transfusions in adults with certain types of myelodysplastic syndromes. The study will also look at how safe and tolerable the treatment is.

Myelodysplastic Syndrome (MDS)Anemia6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Huntington's Disease: Innovative Biomarker Study

We are exploring new imaging and cognitive markers to better understand how Huntington's disease progresses. This study aims to identify effective ways to track the disease from early stages.

Huntington's DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Multiple Myeloma: Belantamab Mafodotin vs. Daratumumab

We are studying a new treatment combination for people with newly diagnosed multiple myeloma who cannot have stem cell transplants. The goal is to see if it works better and is safer than the current standard treatment.

Multiple MyelomaConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Ifinatamab Deruxtecan for Metastatic Prostate Cancer

We are studying ifinatamab deruxtecan to see if it is safe and effective for men with metastatic castration-resistant prostate cancer. This trial will help us understand how well it works compared to other treatments.

Metastatic Castrate Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Kamada-AAT for Inhalation in Alpha-1 Antitrypsin Deficiency

We are studying a new inhalation treatment for adults with congenital Alpha-1 Antitrypsin Deficiency to see if it improves lung function compared to a placebo. The trial also looks at safety and immune responses to the treatment.

Congenital Alpha-1 Antitrypsin Deficiency>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Cancer Imaging: New Non-Invasive Technique

We are exploring a new imaging method that combines two techniques to study how cancer cells and healthy tissues use energy. This may help improve cancer diagnosis and treatment strategies.

Pancreatic Neuroendocrine TumorNeuroendocrine CarcinomaSoft Tissue Sarcomas>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementAllergologyCardiologyDermatologyDiabetologyEndocrinologyGastroenterologyGynecology and ObstetricsHematologyInfectious DiseasesInternal MedicineNephrologyNeurologyOncologyOrthopedics and TraumatologyOtolaryngologyPediatricsPsychiatryPulmonologyRheumatologyUrology

B-Cell Lymphoma: Valemetostat Tosylate Study

We are testing a new treatment for patients with relapsed or refractory B-cell lymphoma. The study aims to see how well it works and its safety across different lymphoma types.

Relapse/Refractory B-Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Stroke Prevention: ASPIRING Study

We are investigating if an oral antiplatelet drug can help prevent serious heart and brain events in stroke survivors. This study compares the effects of this medication to standard care without antiplatelet drugs.

Intracerebral Hemorrhage>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal MedicineNeurology

Liver Transplant: QEL-001 Treatment Study

We are testing a new CAR T cell therapy for patients who received an HLA-A2 mismatched liver transplant. The goal is to evaluate its safety and how well it works in this specific group.

Liver Transplant Rejection3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine

Psoriatic Arthritis: Sonelokimab Treatment Study

We are investigating whether sonelokimab can effectively reduce symptoms in adults with active psoriatic arthritis who have not yet tried biologic treatments. The study will also assess the safety of this new medication compared to a placebo.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Psoriatic Arthritis: Sonelokimab Study

We are investigating the effects of sonelokimab in adults with active psoriatic arthritis who haven't responded to other treatments. This study compares sonelokimab to a placebo and an existing medication to see how well it works.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Cryoglobulinemia Vasculitis: Belimumab Study

We are studying whether belimumab can help people with non-infectious active cryoglobulinemia vasculitis compared to a placebo. The goal is to see if it improves symptoms and overall health.

Cryoglobulinemia Vasculitis6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementInfectious DiseasesRheumatology

Acute Demyelinating Syndromes in Children: Azathioprine vs. Rituximab

We are studying whether starting treatment immediately with azathioprine or rituximab helps children with anti-MOG antibodies better than delaying treatment until a second attack. The goal is to see which method reduces relapses and improves health outcomes.

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyRheumatology

Hereditary Angioedema: Deucrictibant Tablet Study

We are evaluating a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The study aims to determine its effectiveness and safety compared to a placebo.

Hereditary Angioedema3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Hereditary Angioedema: Deucrictibant Extended-Release Tablet

We are studying a new oral medication to prevent angioedema attacks in adolescents and adults with hereditary angioedema. The trial will evaluate its safety, effectiveness, and impact on quality of life.

Hereditary Angioedema>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyInternal Medicine

Sjögren’s Disease: Sibeprenlimab Treatment Study

We are investigating whether Sibeprenlimab can improve symptoms in people with Sjögren’s Disease compared to a placebo. The study will also look at the safety and tolerability of this new treatment.

Sjögren's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInfectious DiseasesRheumatology

Prucalopride for Refractory Gastro-Esophageal Reflux Disease

We are testing a new medication for patients with GERD who still have symptoms despite taking standard treatments. The goal is to see if this drug can improve their reflux symptoms.

Gastro-esophageal Reflux Disease (GERD)≤3 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Type 3 Spinal Muscular Atrophy: NMD670 Study

We are testing the safety and effectiveness of NMD670 in adults with Type 3 spinal muscular atrophy. The study aims to see if it improves muscle strength and function compared to a placebo.

Spinal Muscular Atrophy Type III3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementNeurologyOrthopedics and Traumatology

TAR-0520 Gel for Folliculitis in Colorectal Cancer Patients

We are testing a new gel to see if it is safe and effective for preventing skin irritation in patients using EGFR inhibitors for colorectal cancer. This study focuses on its use on the face and chest.

Papuloerythematous Drug EruptionEGFR Inhibitor-Induced Folliculitis1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDermatologyOncology

Gastric Cancer Treatment: GASTRICHIP Trial

We are comparing two surgical treatments for advanced gastric cancer to see if adding chemotherapy during surgery improves survival rates. This study involves patients with specific stages of gastric adenocarcinoma.

Stomach Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyOncology